Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting, HighFive, and thanks.
HLCSQ: BK effective. All shares cancelled:
http://www.otcbb.com/asp/dailylist_detail.asp?d=03/28/2014&mkt_ctg=NON-OTCBB
yes to see where Helicos assets have gone...you will have to look through future Illumina and Life sciences filings to see the revenue generated....oh and while you are at it look at the former office neighbours (right across the hall) of Helicos...FMI on Nasdaq...JP morgan took these guys public this past year...then look at the chp 11 bankruptcy filings and watch how long the process takes...statute of limitations for financial fraud is what five years? (JPM and other naked shorters are almost out of the woods)
you would think this bankuptcy was as complex as an airlines chp 11 what with all the unions etc etc but no what we see here is feet dragging, deflection and slow torture for existing shareholders who are out of luck and have but a slivers chance of redemption thats assuming the courts and the sec approve the remaining asset sale to an helicos employee(who has the money)...think about that they were struggling to raise capital and all they had to do was send an inter office memo andf they would have been fine...
this deal stinks
the people behind this deal stink
wall street stinks the regulators stink
Brown Ruddic stinks (oh I didnt know we put w lien on all of their IP assets when in reality it should have been the assets that the law firm was engaged to work on....
the seat warmer CEOs thaqt did absol;utley nothing and were just paid to dim the lights...
in the mafia world this scam is called the bust out....take and take and take until nothing is left then strip away whats left of value and move on all the while everyone involved gets paid and gets cushy new jobs or access to capital to finance their next great science experiment
and all of us got a very valuable MBA lesson from Harvard/ MIT lecturers and graduates and other cambridge Mass area VCs on how to raise over $150 million dollars over the course of HLCS NASDAQ life (7 years ago ipo 4 to 5 years ago monkey business started to set in) and then when completed how to transfer and strip the assets/IP out of the company via CHP 11 bankruptcy all squeky clean and legal like...
Hello, hello, is anyone out there? Help I'm a rock!
Wow... so HLCS went into Bankruptcy... Those hedge funds probably gave back the stock so their can be a debtholder to the company. When they get thru their bankruptcy then they may have a chance to the stock in the new company, What a shame!!
Hello High5. I noticed on the BK petition each of the founding VC's have given up 5.35 million of their shares from the April17 2012 10K/A filing. That works out to 24.57% of the outstanding (87,033,038. Shares were not canceled and the filing was certified by Jeff Moore.
Why Steven Chu ? He was on th scientific advisory board due to his past at Stanfors with Steve Quake. This from Wikipedia
While at Stanford, Chu's research interests expanded into biological physics and polymer physics at the single molecular level. In the field of biological physics, he studied enzyme activity and protein and RNA folding using techniques such as fluorescence resonance energy transfer, atomic force microscopy, and optical tweezers. Chu's research in polymer physics made use of individual molecules of DNA to study polymer dynamics and phase transitions associated with these dynamics. He further continued his research in atomic physics as well, developing new methods of laser cooling and trapping.[18]
Depends on your source. Could be just a tout to help the short sellers build their positions. Cheers
What a shame...
this is one of the first pennies I bought...
rode it from $1 to $3
...and all the way down to 10¢
before I sold!
Lesson learned...
Have always kept it on my watch list.
I really hoped they'd make it.
HLCS changed to HLCSQ:
http://www.otcbb.com/asp/dailylist_detail.asp?d=11/21/2012&mkt_ctg=NON-OTCBB
That is quite a rumor. Where might you have heard such a thing?
Rumor could be BS but word is that Steven Chu is joining the board or will be active with helicos again...why i do not know because he is currently sec of energy
anyways take with massive grain of salt... what does he have to do with helicos?
interesting
and now Noubar Afeyan and Barret resigned today.
time for changes and to move on. I still am shocked that the trial ended like it did...but I got a funny feeling things my start sinking into place
Well that certainly didn't take long. Judge threw out the case against Illumina.
Law360, New York (August 29, 2012, 3:15 PM ET) -- A patent infringement crusade
embarked upon by Helicos BioSciences Corp. ended on Tuesday as a Delaware
federal judge found Helicos' remaining genetics analysis patent invalid, letting
Illumina Inc. off the hook for allegedly incorporating it into its scanning
technology.
U.S. District Judge Sue L. Robinson allowed Illumina, the last remaining
defendant in the case, to exit after determining that the genetics analysis
invention asserted by Helicos was not covered by the language of its patent
description, granting Illumina's motion for summary judgment on invalidity.
"In sum, and based on the record created by the parties, the court concludes
that Illumina has demonstrated, by clear and convincing evidence, that the
written description requirement has not been met," Judge Robinson said, finding
that the language of the patent-in-suit failed to specifically outline the
nature of the illumination system utilized in the analysis invention.
"The court has been unable to reconcile the language chosen by the inventor to
describe his invention and the science at issue," the judge said. "Given this
Hobson's choice, the court finds the [patent] invalid for lack of written
description and enters judgment in favor of Illumina."
Helicos first raised the instant suit in August 2010, ultimately bringing patent
infringement allegations against Illumina, Pacific Biosciences of California and
Life Technologies Corp.
Cambridge, Mass.-based Helicos is a life sciences company that develops genetics
analysis techniques for the research, discovery and clinical diagnostics
markets. Its lawsuit against Illumina and the other defendants asserted a total
of five separate patents, including U.S. Patent Number 7,593,109, titled,
"Apparatus and methods for analyzing samples," issued in September 2009.
Though Pacific Biosciences and Life Technologies managed to exit the suit
earlier this year — with the U.S. Patent and Trademark Office having rejected
several of the patents asserted against them — Illumina remained a defendant to
allegations it infringed the '109 patent through the San Diego-based company's
genetics scanning devices. Both Helicos and Illumina had moved the court for
summary judgment — Illumina asserting noninfringement and patent invalidity and
Helicos asserting infringement.
The '109 patent discloses an apparatus and method for analyzing biological
samples by which a vacuum source pulls a microfluidic volume through analytic
equipment and optics are in turn used to analyze the material contained in this
volume. This optics system, as described in the patent, consists of a light
source used for analysis and a second light source used to assess the path of
the main source.
According to Illumina, the '109 patent language fails to set out just how this
second "focusing" light source works, claiming that this lack of specificity
dooms the patent's validity. Judge Robinson on Tuesday agreed.
"Although the parties seem to agree on the ordinary meaning of the word 'focus'
… the complete limitation is in dispute," the judge said. "The parties agree
that varying the angle of the optical path of the analytical light source will
not make the image sharper or more in focus and the specification, not
surprisingly, contains no description of such."
Accordingly, the judge said, the '109 patent is invalid.
Representatives for the parties were not immediately available for comment on
Wednesday.
The patent-in-suit is U.S. Patent Number 7,593,109.
Helicos is represented by Richard D. Kirk and Stephen B. Brauerman of Bayard PA
and Douglas J. Kline, Daniel M. Forman, Brian A. Fairchild, Sheryl Koval Garko
and Kurt M. Kjelland of Goodwin Procter LLP.
Illumina is represented by Steven J. Balick and Lauren E. Maguire of Ashby &
Geddes PA, and Jeffrey N. Costakos and Rebecca Jan Pirozzolo-Mellowes of Foley &
Lardner LLP.
The case is Helicos Biosciences Corp. v. Illumina Inc., case number
1:10-cv-00735, in the U.S. District Court for the District of Delaware.
http://www.law360.com/ip/articles/373868/helicos-genetics-patent-ruled-invalid-i\
n-illumina-row
settlement or sediment?
Because Helicos did have quite the case with the 109 patent. Why would they settle? if not for a big cheque? or to finally move on and grow again, enough of court!... If Stan the man was still at Helicos I would breathe easier as he and quake were the soul of the Company. Since these new guys have come in, I dont know what to expect...their sweat isnt in this, they were just handpicked to come in and manage a transition (albeit one that wouldnt come into effect until the trial ends). What this transition is? I do not know. But as it stands now, it cannot carry on like it has been for the last few years...if its true that the trial is cancelled and we have a settlement in our favour (regardless of size of payout although the more the merrier)then the next chapter will begin. I am hoping this chapter is filled with more upside and less grief for shareholders.
I trust Stan Lapidus judgement in regards to who is running things now at Helicos. Stan' legacy and rep is tied with this Company, a high profile failure of a start up is something I know he doesnt want to have on his CV. Makes it harder to attract talent if your last venture blew up...and forget the money men and finaciers they are less forgiving.
And the very next day the trial between Helicos and Illumina (patent 109) is cancelled.
From PACER:
The pretrial conference set for 8/30/2012 and jury trial set for 9/10/2012 have
been CANCELLED per the joint request of counsel.
ILLUMINA desperate to lid this,
tried moving venue didnt work...
now they have been trying to suppress this expert...who had this to say about single molecule DNA analytics
this is what he wrote way back in late 2009 and early 2010 for "annual review of Analytical chemistry"
The ability to detect single molecules of DNA or RNA has led to an extremely rich area of exploration of the single most important biomolecule in nature. In cases in which the nucleic acid molecules are tethered to a solid support, confined to a channel, or simply allowed to diffuse into a detection volume, novel techniques have been developed to manipulate the DNA and to examine properties such as structural dynamics and protein-DNA interactions. Beyond the analysis of the properties of nucleic acids themselves, single-molecule detection has enabled dramatic improvements in the throughput of DNA sequencing and holds promise for continuing progress. Both optical and nonoptical detection methods that use surfaces, nanopores, and zero-mode waveguides have been attempted, and one optically based instrument is already commercially available.
Dr. Shimon Weiss
apparently Illumina is desperate to not let this guy speak or testify anything on behalf of Helicos...he is well respected within his field.... ILMN has filed a motion to strike his testimony...some say its because it is clear cut and will make sense for any jury
to this date the court hasnt ruled on this...but my feeling is if he isnt allowed to speak or if his testimony is removed, then its up in the air although I still believe HLCS will win..
IF
Dr Shimon Weiss is allowed to speak or testify on behalf of helcos either verbal or written, then he will surely make this case a slam dunk for HLCS as Dr. Shimon Weiss has a knack of taking abstract, theoritcal hi end concepts and simplify them in laymen terms that can easily be digested by any jury
one last point? how many of these machines has Illumina sold?
trusted in the hands of a jury who are sick of bullied corps ripping off and beating up little guys and amassing fortunes doing so, if I was an attorney for Illumina I would never let it get to the jury....are you kidding me?
SO Helicos Light system uses 2 sources of Light while the Illumina one (Slide 29 previous post) uses one light source (a laser) but encloses it "thus Internal TIRF" and adds the reflective prism
so does Helicos IP rely on the number of light sources as its backbone? or is the "novelty" of its lighting system ITSELF the patent.....
its simple really Illumina knows that it is offside on this thus the failed attempt to move trial venues....they wanted to delay and stall and starve out helicos....
http://sfgf.stanford.edu/documents/solexa_docs/Technology_Overview/general_technology.pdf
read helicos patent then look at slide or page 28 and 29
from helicos patent....
The present invention involves using a vacuum source to pull microfluidic volumes through analytical equipment, such as flow cells and the like. Generally, the invention includes a passive vacuum source and one or more valves and sensors for operating and monitoring the apparatus and methods. Additionally, the invention involves using optical equipment in conjunction with the analytical equipment to analyze samples and control the operation thereof.
In one aspect, the invention relates to a lighting system including a first light source for analyzing a sample of interest and a second light source. The first light source defines a first optical path that intersects a sample of interest and the second light source operates with the first light source for determining a position of the first optical path
HELICOS PATENT 109 IN a nutshell
1. A system for analyzing a sample, comprising:a flow cell;a lighting system for illuminating the sample in the flow cell; andan optical instrument for viewing the sample in the flow cell,wherein the lighting system comprises:one or more analytical light sources, each light source defining an optical path that intersects the sample; anda focusing light source operating with any one of the analytical light sources to focus said optical instrument on the sample.
read the above Helicos patent then click on the Illumina slide number 29 read the Helicos patent and view slide 29
All Illumina did with the TIRF was made it "Internal" so they basically just hid it in one of their machines lol
you see, they have the Big mac, I have the Big Mic....we both use two all beef patties special sauce lettuce cheese...EXCEPT my burgers dont use a sesame seed bun
Mr Mcdowell in "Coming to America"
109 PATENTS
BACKGROUND
Generally, systems for analyzing a sample in a flow cell are pressure driven fluidic systems using pressure pumps. Pressure driven fluidics systems have several disadvantages. One disadvantage is that pressure driven systems require the sample vessel to be sealably engaged to the flow cell assembly. This makes removal of the flow cell more complicated, because removal of the flow cell can produce hazardous aerosols. Pressure systems are also known to develop system leaks due to the pressure and may require frequent replacement of lines and valves. Additionally, pressure driven systems can introduce contaminants into the sample. Another disadvantage of pushing fluid through the system is that air can become trapped in the system or air bubbles can be introduced into the sample. Introduction of air into the pump can cause cavitation resulting in shock to the system. Moreover, in pressure driven systems, it is difficult to adequately purge the lines after each sample has been tested. This can result in residual material being left in the system when the next test is performed. Also, purging the system using air pressure tends to cause bubbling or foaming in the samples, which may introduce inaccuracies to the analysis.
The prior art vacuum driven systems that have been used to analyze samples in a flow cell also have disadvantages. In these prior art systems, a vacuum pump is directly connected to the flow cell. Again, the use of a pump can cause air bubbles to be introduced into the sample and air trapped in the pump transmit shock to the system. Additionally, the continuous on and off cycle of the pump can result in uneven passage of a sample through the flow cell. Prior art vacuum systems are also generally suited for passing multi-cell samples through the flow cell. Having a pump directly connected to the flow cell can negatively impact single-cell samples, in part, because of the shock transmitted to the system.
In analyzing microfluidic volumes and related biological materials using a light source, . The excited fluorophores can be observed using, for example, an intensified CCD camera. Accurately maintaining the critit is desirable for the light source to hit the sample in such a way that results in total internal reflection fluorescence ("TIRF"). TIRF is an optical phenomenon that occurs when light propagating in a dense medium, such as glass, meets an interface with a less dense medium such as water. If the light meets the surface at a small angle, some of the light passes through the interface (is refracted) and some is reflected back into the dense medium. At a certain angle, known as the critical angle, all of the light is refracted. However, some of the energy of the beam still propagates a short distance into the less dense medium, generating an evanescent wave. The evanescent wave only penetrates about 100 nm into the medium. If this energy is not absorbed, it passes back into the dense medium. However, if a flourophore molecule is within the evanescent wave, it can absorb photons and be excitedical angle to obtain TIRF in a dynamic system is difficult.
SUMMARY OF THE INVENTION
The present invention involves using a vacuum source to pull microfluidic volumes through analytical equipment, such as flow cells and the like. Generally, the invention includes a passive vacuum source and one or more valves and sensors for operating and monitoring the apparatus and methods. Additionally, the invention involves using optical equipment in conjunction with the analytical equipment to analyze samples and control the operation thereof.
In one aspect, the invention relates to a lighting system including a first light source for analyzing a sample of interest and a second light source. The first light source defines a first optical path that intersects a sample of interest and the second light source operates with the first light source for determining a position of the first optical path.
In various embodiments of the foregoing aspect, the first light source and the second light source operate simultaneously. The second light source may define a second optical path at least partially coaxial with the first optical path. In one embodiment, the second light source is directed to a position sensor for sensing an angle of reflection of the first optical path relative to the sample of interest. The position of the first optical path can be adjusted to vary the angle of reflection in response to a signal from the position sensor. The position of the first optical path can be adjusted to obtain substantially total internal reflection of the first light source relative to the sample of interest.
Additionally, the first light source can have a wavelength from about 390 nm to about 780 nm. In one embodiment, the second light source is infrared light. The first light source and/or the second light source can be a laser, a light emitting diode, or a lamp. In one embodiment, the system includes an imaging device for imaging the sample of interest. Further, the system can include a third light source for analyzing the sample of interest. The third light source can define a third optical path at least partially coaxial with the first optical path. The first light source and the third light source can be operated simultaneously. The second light source may be used to continuously monitor the position of the first optical path. In one application, the light system can be adapted for use in a single molecule sequencing system.
In another aspect, the invention relates to a method of substantially maintaining total internal reflection for a sample of interest. The method includes the steps of providing a first beam of light for intersecting with the sample of interest, providing a second beam of light for determining a position of the first beam of light, directing the second beam of light onto a position sensor, and adjusting the position of the first beam of light in response to a signal from the position sensor to vary an angle of reflection of the first beam of light with respect to the sample of interest to substantially maintain total internal reflection.
In various embodiments, the first beam of light is at least partially coaxial with the second beam of light. The first beam of light is for analyzing the sample of interest. In one embodiment, the first light source has a wavelength from about 390 nm to about 780 nm. The second light source may be infrared light. The method may also include the steps of continuously monitoring the position of the first beam of light and adjusting the angle of reflection in response thereto to substantially maintain total internal reflection.
In another aspect, the invention relates to a system for analyzing a sample. The system includes a flow cell, a passive vacuum source for pulling a volume through the flow cell, a lighting system for illuminating the sample in the flow cell, and an optical instrument for viewing the sample in the flow cell. The lighting system can be of the type described hereinabove. In one embodiment, the volume includes the sample or agents for reacting with the sample, which may be predisposed on or within the flow cell. Alternatively or additionally, the sample may adhere to or come to rest within the flow cell while the volume passes therethrough. In one embodiment, the volume and/or sample is moved through the flow cell by gravity. For example, the head pressure on the volume within an inlet to the flow cell is sufficient to move the volume through the flow cell.
In various embodiments of the foregoing aspect, the system includes a stage for receiving the flow cell, where the stage is movable in at least one direction. In one embodiment, the stage is movable in two orthogonal directions. The system may also include an image capture device for capturing an image of the sample. The image capture device can be a charge coupled device (CCD), a complementary metal oxide semiconductor device (CMOS), a charge injection device (CID), or a video camera. Additionally, the system could include a processor for collecting and processing data generated by the system, storage for storing the data, and means for displaying at least one of the data and the sample.
In another aspect, the invention relates to an apparatus for handling microfluidic volumes, such as biological samples for analysis. The apparatus can include the aforementioned passive vacuum source and flow cell. The microfluidic volume is pulled through the flow cell by the passive vacuum source. In one embodiment, the passive vacuum source includes a pump, a pump driver, such as an electric motor, and a reservoir. The pump can be connected to the reservoir and then operated to evacuate the reservoir, thereby creating a vacuum within the reservoir. In one embodiment, the vacuum pressure is from about 1'' Hg to about 29'' Hg. The vacuum pressure can be adjusted to vary the speed at which the microfluidic volume passes through the flow cell.
In various embodiments of the foregoing aspects, the apparatus/system can be used for single molecule detection. In one embodiment, the flow cell includes a surface for receiving a nucleotide. For example, the flow cell can include a bound nucleotide and a primer bound to the nucleotide and/or the flow cell. In particular, the flow cell can include a slide and a coverslip, where the nucleotide and/or the primer are bound to at least one of the slide and the coverslip. Additionally, the flow cell can include a channel for pulling the microfluidic volume therethrough.
In some embodiments of the foregoing aspects, the ratio of a volume of the reservoir and the microfluidic volume is between about 1,000:1 and about 2,000,000:1, or between about 50,000:1 and about 1,000,000:1, or about 200,000:1. Further, the apparatus can include valving disposed between the various components thereof. For example, the apparatus can include a valve disposed between the vacuum source, for example the reservoir, and the flow cell, wherein the valve includes an open position to connect the flow cell to the vacuum source and a closed position to isolate the flow cell from the vacuum source. The apparatus can also include a vacuum pressure indicator connected to the reservoir. Moreover, the apparatus can further include optical equipment for analyzing material within the flow cell after exposure to the microfluidic volume.
In another aspect, the invention relates to a method of detecting single molecules. The method includes the steps of depositing a sample comprising single molecules into a flow cell, the flow cell treated to identify specific molecules; applying a vacuum to the flow cell; pulling the sample through a channel defined by the flow cell; and viewing the flow cell after exposure to the sample to identify the molecules exposed to the flow cell.
In another aspect, the invention relates to a method of detecting single molecules. The method includes the steps of providing a flow cell that defines a channel that is treated to identify specific molecules, applying a vacuum to the channel to pull a sample through the channel, the sample comprising single molecules, and viewing the sample in the channel to identify the single molecules.
Various embodiments of the foregoing methods include the step of removing the vacuum from the flow cell after pulling the sample through the channel. The step of applying a vacuum can include exposing the flow cell to a passive vacuum source. In various embodiments, the sample includes a microfluidic volume including nucleotides. Additionally, the flow cell can include at least one of a slide and a coverslip treated to bind with a specific nucleotide. Further, the step of viewing the flow cell can include illuminating the flow cell with a lighting system, such as that described hereinabove. The step of viewing the flow cell can also include using an image capture device. In one embodiment, a processor is used to control the operation of the method. The processor can be used for collecting and processing data generated during the method. The method can further include the step of displaying at least one of the flow cell and the data.
In another embodiment, single nucleotide detection is accomplished by attaching template nucleic acids to a flow cell in the presence of a primer for template-dependent nucleic acid synthesis. Using a device according to the invention, a vacuum is created across the flow cell for introduction of reagents for template-dependent nucleic acid synthesis. For example, once template/primer pairs are bound to the surface of the flow cell, reagents comprising labeled or unlabeled nucleotides and a polymerase to catalyze nucleotide addition are added via an entry port. The vacuum is switched on and the reagents are exposed to the flow cell and then exit via an exit port to the reservoir. After a wash step, complementary nucleotides added to primer are detected. Preferably, reagent nucleotides are labeled with, for example, a fluorescent dye. Such dyes are observed using light microscopy. For example, cyanine dyes (cyanine-3 or cyanine-5) are useful for optical detection of incorporated nucleotides. Using optically-detectable labels, nucleic acid sequencing is conducted on a single molecule level. This means that individual template nucleic acids are positioned on the flow cell such that each is individually optically resolvable. The location of the templates is determined by, for example, the use of dye-labeled primers that hybridize to individual templates. Labeled nucleotides are flowed across the flow channel using the mechanisms described herein under conditions that allow complementary nucleotide addition to the primer. Once incorporated, the label is detected by excitation of the dye at the appropriate wavelength and by using an emission filter for detection of the emission spectrum. Emissions that occur at a location known to contain a template indicate incorporation of the labeled base at that position. By conducting these steps multiple times, a sequence is completed. Single molecule sequencing techniques are described in Braslavsky, et al., PNAS (USA), 100: 3960-3964 (2003) and copending U.S. patent application Ser. No. 09/707,737, each of which is incorporated by reference herein.
In another aspect, the invention relates to a flow cell for analyzing single molecules, such as nucleotides. The flow cell includes a slide, a coverslip, and a gasket disposed between the slide and the coverslip. The slide, the coverslip, and the gasket define a microfluidic channel for passing single molecules under vacuum. In various embodiments, the flow cell includes a nucleotide bound to the slide and/or the coverslip. In addition, the flow cell can include a primer bound to at least one of the nucleotide, the slide, and the coverslip. In one embodiment, the slide includes a plurality of nucleotides bound thereto.
In another aspect, the invention relates to a slide for use with a flow cell. The slide can include at least one nucleotide bound to a surface of the slide. The slide can be disposed within the flow cell. The slide can further include a primer bound to at least one of the slide and the nucleotide. In addition, the slide can include a plurality of nucleotides bound thereto.
In another aspect, the invention relates to a coverslip for use with a flow cell. The coverslip includes at least one nucleotide bound to a surface of the coverslip. The coverslip can be disposed within the flow cell. The coverslip can further comprise a primer bound to at least one of the coverslip and the nucleotide. In one embodiment, the coverslip includes a plurality of nucleotides bound thereto.
These and other objects, along with advantages and features of the present invention herein disclosed, will become apparent through reference to the following description, the accompanying drawings, and the claims. Furthermore, it is to be understood that the features of the various embodiments described herein are not mutually exclusive and can exist in various combinations and permutations.
TRIAL SOON APPROACHES Sept its on...
and the helicos lawyers did such a nice job bringing in this "onion" kind of legal case...
109 patent is the spine and core of the whole arguement...everything was thrown in there so as the discussions and process moved forwad.....layers peeled away......little concessions and settlements are made...making Helicos look all so rationale and respectful to court and the due process....something the jury will be very happy to see...
109
109
109
it was always a 109... but when you go to trial you throw as much arbage on the wall as you can hoping it sticks....like prosecutors do when they go trial they will add all sorts of charges to the case so there is some leverage or give and take that can be done...but the CORE charge...the raison d'etre for going to trial the reason for the talk of the injunctions and such are the 109 patents...
Life was released because althought they were developing 3 gen tech using some of Helicos IP...the simple fact was that LIFE had not sold or made a dime from any of helicos ip....THEY WERE ADDED TO SLOW THEIR DEVELOPMENT DOWN AND KEEP EM HONEST
PACB and ILMN BOTH mae money using Helicos IP.... although PACB made very little the target has always been on Illumina and the 109 patent....
its funny Illumina being sued because of its illuminating system within its machines
GOOD!!
First Claim
1. A system for analyzing a sample, comprising:a flow cell;a lighting system for illuminating the sample in the flow cell; andan optical instrument for viewing the sample in the flow cell,wherein the lighting system comprises:one or more analytical light sources, each light source defining an optical path that intersects the sample; anda focusing light source operating with any one of the analytical light sources to focus said optical instrument on the sample
http://www.patentbuddy.com/Patent/7593109
July 30, PACB reports. Keep your eye on the prize for settlement data .
http://data.cnbc.com/quotes/PACB/tab/5
New paper out on Nature.
http://www.nature.com/nature/journal/vaop/ncurrent/full/nature11217.html
Massachusetts General Hospital Cancer Center, Center for Engineering in Medicine, and Departments of Medicine and Surgery, Harvard Medical School, Boston, Massachusetts
Howard Hughes Medical Institute, Chevy Chase, Maryland
Helicos BioSciences Corporation, One Kendall Square, Cambridge, Massachusetts
Paper has been in review since July 2011 just published. Coincidence a settlement is close to being finalized with Illumina?
Anyone have a better translation?
http://www.microsofttranslator.com/BV.aspx?ref=IE8Activity&a=http%3A%2F%2Fwww.ebiotrade.com%2Fnewsf%2F2012-6%2F2012619153046149.htm
Recent court filings suggest that' ilmn and Hlcs have come to terms on 2 of the 3 disputed patents.....and pacb files in july they can hold off until 15th of aug and no longer they have to disclose the settlement...
This has alot more spark.
https://twitter.com/#!/Helicos_Bio
for all practical purposes this is dead...
They tell you right there in the quarterly, that even so that the payout could be big, there will be nothing for the shareholders.
Everything has been quartered out and we were not invited to sit at the table.
They got our money and in essence they are telling to go screw off.
This is transferring public assets from a public company to private concerns thru the use of collaterized notes.
The only chance you have to fight this is to hire a good attorney to start a class action lawsuit and to name all the vc in on the lawsuit and then possibly can get some back to the public company and to us shareholders...otherwise this is dead.
sorry to be down just hate this management for their silence and lack of market ir savvy and self serving moves...
pardon the horse racing analogy
we have the "secretariat" of the SMS tech out there but unfortuantley our jockey is to busy calling up glue factories and getting quotes instead of trying to make a go of it...
can anyone tell me other than the lawsuit what is their plan?
molecular diagnostic tests that would tackle brca...never mentioned again
setting up their lab....abandoned
partnering with a large pharma to slavage the tech?
not until the vampire capitalists (VC) are done sucking this tech and locking in cheap ass licenesing agreements for their other start ups that they are incubating....
we are getting cheated by having a part time ceo and no IR to speak with and no one to talk to...went down to pinks so they wouldnt have to do an AGM....they dont want to deal with us...
Yes, it looks like the stock is going to be stuck in a yo-yo pattern between .06 and .08 until some more news comes.
That's when it ramped up in 1q... Anyways until part time CEO Ivan decides to make moves and offer support we will be plagued with 24 dollar trades at 400 shares low print that knock us to .06
Management is neglectful and just doesn't care...
Were they claiming that their machines were running 24/7 during the first quarter too?
The April 1.3 million dollar sale to Sequenom gave them a much needed shot of fuel. Hopefully, more sales to come. I believe Helicos has already beaten last year's second quarter revenues with the patent sale.
What I am hoping for is a settlement...Or maybe a buyout... Combined ilmn and life have a
OT of cash on hand and any buyout of helicos would make sense...since both are touting single molecule seq as the future...
The change of venue request was a cheap stall tactic that was the last one they could throw before prep for trial...once that was thrown out you can't help but think there was a switch in attitude towards the trial... I'm hoping that there have been talks amongst the lawyers but unfortunatley until we see any court docs we can only speculate
It all comes to a head in August and September ... The question..if you read the helicos unveiled twitter account... They are running their machines 24 /7 who are they sequencing for? What revenue comes to helicos? Are we on autopilot until the court case or is this company still doing business?
or do you think we will see more pre-trial settlements?
Any time frames on the other court cases?
It should but we just don't have the details yet....
Ilmn and life are the big ones helicos seeking large payouts
Ve vill know in Q2 reports from PACbio vhat the settlement was as THEY CANOT HIDE IT FROM ther shareholders. The settlement happened in Q2 so the amount vill be reflected in pacbio q2 filings.
So mr. bommblehgead trifanovish . . i know yu read this.
Put the numbers out.
Get the share price over $1
reaply to NASday
Raise capital
Get business off the guter.
.kindest regards.
bb
Does this indicate a new ongoing revenue stream? If so, why wouldn't Helicos disclose the terms?
Poor management no other way to see it
Something is off with these guys
"Helicos Confirms Licensing Deal with PacBio as Part of IP Settlement" May 14, 2012
"NEW YORK (GenomeWeb News) – Helicos BioSciences confirmed today that it has settled patent infringement litigation with Pacific Biosciences and has entered into a licensing deal.
Terms of the settlement were not disclosed.
PacBio disclosed the settlement when it announced its first-quarter 2012 financial results earlier this month, saying it had taken a $1.8 million charge related to the resolution of two separate lawsuits involving Helicos and Life Technologies.
PacBio Vice President of Finance and Treasurer Ben Gong told GenomeWeb Daily News at the time that the two settlements did not include licensing deals. But, in a recent Form 10-Q filed with the US Securities and Exchange Commission, PacBio disclosed it is licensing patents rights to technology from Helicos.
Helicos, headquartered in Cambridge, Mass., confirmed the licensing agreement in its announcement today.
"After carefully evaluating sales trends in the next-generation sequencing marketplace over the last several quarters, including the trend in Pacific Biosciences' sales, and balancing potential future recovery versus litigation cost, we have concluded that the best course of action for Helicos is to settle with Pacific Biosciences," Helicos President, Chairman, and CEO Ivan Trifunovich said in a statement. "The settlement and the associated non-exclusive and non-sublicensable license are narrowly focused on Pacific Biosciences's own technology.".......
...Helico sued PacBio in the summer of 2010 alleging the Menlo Park, Calif.-based next-generation sequencing firm infringed on US Patent Nos.7,645,596; 7,037,687; 7,169,560; and 7,767,400. Helicos later included Illumina and Life Technologies as defendants in the lawsuit.
Today, Trifunovich said that with its case against PacBio concluded, Helicos' attention will be directed at those two companies, "and we plan on continuing to pursue vigorously the patent infringement cases against them."
Link:
http://www.genomeweb.com/sequencing/heli...
In the press relaes it states they are going to continue patent infringment claims against Illumina and Life Technologies. Getting a pay out from Pacific Biosciences I would imagine puts them in a positive postion against the other defendants.
Close to the vest!?!!!???!!!
Have you read the filings today? I think they swallowed the cards....
Undisclosed financial amount...
Why the secrets? I don't understand....
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
684
|
Created
|
08/23/07
|
Type
|
Free
|
Moderators |
IR and PR for Helicos: MacDougall Biomedical Communications, Chris Erdman, 781-235-3060,cell: 617-686-1718, e-mail: chris@macbiocom.com
http://finance.yahoo.com/q/ks?s=HLCS
Helicos BioSciences Corporation, a life sciences company, engages in the development of genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets. The company is incorporating its proprietary True Single Molecule Sequencing technology into its commercial product consisting of an instrument called the HeliScope and its associated reagents and supplies. It intends to offer the HeliScope, which is used to enable ultra-high-throughput genetic analysis based on the direct sequencing of single molecules of DNA or single copies of RNA. The company intends to sell its system in North America, Europe, and Asia. Helicos BioSciences Corporation was founded in 2003 and is headquartered in Cambridge, Massachusetts.
|
|
|
tSMS™ Technology Demo :: | |||||
| |||||
Popular Links :: | |||||
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7931967
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |